A paper presented at the 2025 ASCRS meeting
reported 18-month interim safety and efficacy results following the implantation of a monofocal intraocular lens (IOL) with mounted sustained-release bimatoprost implant in eyes with mild to moderate open-angle glaucoma or ocular hypertension.
